On behalf of IFARA, CARE community advisory board coordinator Jeff Taylor spoke with Jordan Lake, M.D., and Todd Brown, M.D., Ph.D., about research on preventing metabolic complications in people who are taking antiretroviral medications. The biggest news was a switch study for tenofovir alafenamide (TAF), a new version of tenofovir, which showed a 2% improvement in bone density for those taking the new form of the drug.
Another concern, chronic inflammation due to HIV, was found to improve in those who are 100% adherent to their medication regimen. While lipodystrophy is still an important issue for people living with HIV, research shows that it is possible to have a lot of body fat without metabolic problems. Overall, Dr. Lake called the period since CROI 2015 "a good year for metabolics."
Watch the video to learn more:
About the panelists:
Todd T. Brown, M.D., Ph.D., Johns Hopkins University, Baltimore, Md.
Jordan Lake, M.D., University of California, Los Angeles, Los Angeles, Calif.
The video above has been posted on TheBodyPRO.com with permission from our partners at the International Foundation for Alternative Research in AIDS (IFARA). Visit IFARA's website or YouTube channel to watch more video interviews from the CROI 2016 conference, as well as earlier meetings.
More Like This
No Need to Adjust for Race When Analyzing Pulmonary Function
From Provider Stigma to Chemsex: HIV Glasgow 2024 Highlights
